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Bedimo and Co-workers have recently reported the results of a prospective, cross-
sectional study aimed at investigating the mechanisms of increased bone loss in male 
subjects with HIV and HCV mono-infections or HIV/HCV co-infections [1]. They 
found that HIV and HCV were significantly and independently associated with lower 
bone mineral density (BMD). The statistical models adjusted for tenofovir (TDF) use 
greatly attenuated the association of HIV with decreased BMD, suggesting that the 
effect of HIV on BMD was mainly driven by TDF. Furthermore, the Authors 
documented that, at variance with HCV, HIV infection was associated also with altered 
bone turnover, as documented by increased telopeptide X (CTX) and osteocalcin (OC) 
serum concentrations. Here we intend to extend these findings by assessing the potential 
contribution of TDF overexposure on bone diseases, in consideration of the recently 
reported associations between high TDF plasma concentrations and the development of 
kidney impairment [2,3].  
 
In this retrospective analysis we included all HIV-infected patients from our local 
database treated with TDF for at least six months and with at least one assessment of 
TDF plasma trough concentrations. Bone diseases were assessed through evaluation of 
BMD by dual-energy x-ray absorptiometry (DXA) (osteopenia and osteoporosis were 
diagnosed as a spine or hip T-score between -1 and -2.5 or < 2.5, respectively) and/or by 
markers of bone formation and resorption such as OC (reference values: 11-46 ng/mL) 
and CTX (reference values: <580, <704 and <1000 pg/mL for all patients <50 years, 
males>50 years and females >50 years, respectively). 198 out of the 478 patients from 
our database fulfilling the inclusion criteria performed at least one DXA evaluation. 
They were at a mean of 2080±1209 days of therapy with TDF and were mainly given a 
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protease inhibitor (54%) or a non-nucleoside reverse transcriptase inhibitor (34%) as the 
third drug of the antiretroviral therapy. Overall, 150 out of the 198 patients (76%) had 
DXA alterations (92 and 90 patients with osteopenia and osteoporosis, respectively). As 
shown in Table 1, these patients had lower body mass index, were older and were 
treated longer with TDF as compared to patients with normal DXA, whereas no 
differences on TDF trough concentrations were found (157±139 vs. 142±136 ng/mL, 
p=0.51). The same trends were confirmed also when repeating the analysis by 
considering only patients with osteoporosis. Data on markers of bone turnover were 
available for 133 out of the 478 patients. Significantly higher TDF concentrations were 
found in patients with altered vs. normal OC levels (TDF concentrations: 288±173 vs. 
153±115 ng/mL, p<0.01). Conversely, no association between TDF concentrations and 
CTX level were documented (TDF concentrations: 147±103 vs. 165±128 ng/mL, 
p=0.74 in patients with altered vs. normal CTX values). 
 
In agreement with previous findings, we firstly documented that a large proportion of 
HIV-infected patients on long-term antiretroviral therapy developed bone metabolism 
alterations; these events were significantly associated with patients’ age and lower body 
mass index [4,5]. We also extended the findings by Bedimo et al [1] by recognizing that 
bone disease was significantly associated with the duration of TDF therapy but not with 
TDF plasma trough concentrations. The latter finding seems to argue against a potential 
contribution of TDF overexposure on the development of bone diseases, at variance 
with findings in HIV-infected patients experiencing TDF-related kidney complications 
[2,3]. This may be eventually related to the fact that, at variance with kidney diseases – 
in which a direct mechanism linked to the selective accumulation of TDF within renal 
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tubular cells has been identified [6-8] – TDF is only one of the risk factors for bone 
loss, and its effect may be eventually diluted by the presence of other clinical covariates 
(such as, patients’ sex, age, diet, body mass index, etc) known to play a key 
pathogenetic role in bone diseases [4,5]. This hypothesis has been indirectly confirmed 
by the findings that patients with altered OCT levels have significantly higher TDF 
plasma trough concentrations compared with patients with physiologic OC levels, 
whereas no association was found with CTX levels. Taken together, these results 
suggest an essential involvement of TDF only in the process of bone formation. Indeed, 
assuming that OC is a marker which a) is secreted solely by osteoblasts, b) is pro-
osteoblastic and c) whose alterations induce pathologic alterations in BMD [9], it can be 
reasonably speculated that the detrimental effects of TDF on bone metabolism might be 
driven mainly by OC-mediated loss of osteoblast function. Accordingly, our results 
provide for the first time in vivo indirect evidence that the effect of TDF on osteoblast 
activity is concentration-dependent, as previously documented in vitro in osteoblast 
cultures [10].  
 
In conclusion, in this hypothesis-generating study we have provided preliminary 
evidence that exposure of patients to high plasma TDF concentrations might induce 
early pathologic alterations in bone turnover, eventually favoring the development of 
osteopenia/osteoporosis through impaired bone formation in high-risk HIV-infected 
patients. 
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Table 1. Patients characteristics clustered according to the development or not of bone 
diseases  
 
Parameters  
No bone  
diseases  
(n=48)  
Osteopenia or  
osteoporosis  
(n=150)  
P-value  
TDF therapy, days  1683 ± 1417  2209 ± 1109  <0.01  
TDF concentrations, ng/mL  142 ± 136  157 ± 139  0.51  
Female gender, %  47.9%  43.3%  0.33  
Age, years  46 ± 10  51 ± 8  <0.01  
Concomitant ARV drugs, %  50% PI  
33% NNRTI  
17% other  
55% PI  
35% NNRTI  
10% other  
0.74  
Body mass index, Kg/m2  23.8 ± 4.6  22.2 ± 3.9  <0.05  
S.creatinine before TDF, mg/dL  0.80 ± 0.19  0.78 ± 0.19  0.65  
S. creatinine last f.u., mg/dL  1.0 ± 0.3  0.9 ± 0.3  0.16  
CD4, cells/mL  585 ± 252  654 ± 286  0.15  
HBV or HCV coinfection, %  38%  43%  0.51  
TDF: tenofovir; ARV: antiretroviral; PI: protease inhibitor; NNRTI: non-nucleoside reverse transcriptase inhibitor; 
f.u.: follow-up; HBV: hepatitis B virus; HCV: hepatitis C virus 
